Köpenysejtes lymphoma: Esetismertetés

Translated title of the contribution: Mantle cell lymphoma: Case report

Leonóra Méhes, Béla Telek, Miklós Udvardy, Ágota Schlammadinger, László Rejto

Research output: Contribution to journalArticle


Mantle cell lymphoma (MCL) is a moderately aggressive disease, which is not curable with chemo-immunotherapy. The median survival duration is short, approximately three years. Most of the patients have advanced stage disease at the time of diagnosis. Fifty percent of the patients show infiltration of the bone marrow, in 25% of the MCL patients the gastrointestinal tract is involved, in 25% of patients leukaemic transformation occurs. The tumor cells express pan-B-cell markers and the T-cell marker CD5. The overexpression of cyclin DI was found as another marker for mantle cell lymphoma. Combined chemotherapy, chemo-immunotherapy, autologous peripheral stem cell (and allogen) transplantation is the treatment of choice. Our two patients had prolonged survival, in spite of missing the best fisrt line therapy. The survival time after the complex treatment (chemo-immunotherapy, irradiation, surgical intervention, autologous stem cell transplantation) was 80 and 90 months, respectively. In addition to the history of two patients, authors review the current treatment options in mantle cell lymphoma.

Original languageHungarian
Pages (from-to)1471-1474
Number of pages4
JournalOrvosi hetilap
Issue number31
Publication statusPublished - Aug 3 2008


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Méhes, L., Telek, B., Udvardy, M., Schlammadinger, Á., & Rejto, L. (2008). Köpenysejtes lymphoma: Esetismertetés. Orvosi hetilap, 149(31), 1471-1474. https://doi.org/10.1556/OH.2008.28411